{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sobrin L"],"funding":["NEI NIH HHS","National Institutes of Health","University of Pennsylvania Core"],"pagination":["25-30"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8380755"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["29(1)"],"pubmed_abstract":["Purpose
To determine if angiotensin converting enzyme-inhibitors (ACE-I) alter the incidence of non-infectious uveitis (NIU).Methods
Patients in a large healthcare claims database who initiated ACE-I (n = 695,557) were compared to patients who initiated angiotensin receptor blockers (ARB, n = 354,295). A second comparison was also made between patients who initiated ACE-I (n = 505,958) and those who initiated beta-blockers (BB, n = 538,109). The primary outcome was incident NIU defined as a first diagnosis code for NIU followed by a second instance of a NIU code within 120 days. For the secondary outcome, a corticosteroid prescription or code for an ocular corticosteroid injection within 120 days of the NIU diagnosis code was used instead of the second NIU diagnosis code. D"],"journal":["Ophthalmic epidemiology"],"pubmed_title":["Angiotensin Converting Enzyme-Inhibitors and Incidence of Non-infectious Uveitis in a Large Healthcare Claims Database."],"pmcid":["PMC8380755"],"funding_grant_id":["P30 EY001583","R21 EY029851"],"pubmed_authors":["VanderBeek BL","Kempen JH","Hubbard RA","Sobrin L","Li A","Yu Y"],"additional_accession":[]},"is_claimable":false,"name":"Angiotensin Converting Enzyme-Inhibitors and Incidence of Non-infectious Uveitis in a Large Healthcare Claims Database.","description":"Purpose
To determine if angiotensin converting enzyme-inhibitors (ACE-I) alter the incidence of non-infectious uveitis (NIU).Methods
Patients in a large healthcare claims database who initiated ACE-I (n = 695,557) were compared to patients who initiated angiotensin receptor blockers (ARB, n = 354,295). A second comparison was also made between patients who initiated ACE-I (n = 505,958) and those who initiated beta-blockers (BB, n = 538,109). The primary outcome was incident NIU defined as a first diagnosis code for NIU followed by a second instance of a NIU code within 120 days. For the secondary outcome, a corticosteroid prescription or code for an ocular corticosteroid injection within 120 days of the NIU diagnosis code was used instead of the second NIU diagnosis code. D","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2025-04-04T01:24:14.831Z","creation":"2025-04-04T01:24:14.831Z"},"accession":"S-EPMC8380755","cross_references":{"pubmed":["33622166"],"doi":["10.1080/09286586.2021.1887284"]}}